TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Concentrating 2024 R&D Plans Mainly on GLP-1 Investigations
Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced $3.6 million in gross proceeds from its registered direct offering. “Most notably, Lexaria intends to use the net proceeds from this offering for research and development (‘R&D’) studies and the associated patent and legal costs. It also intends to use the funds for general working capital purposes, important for its current focus on GLP-1 clinical studies for the 2024 calendar year… In 2023, Lexaria laid the groundwork for its GLP-1 clinical studies. The company achieved positive interim and final human pilot study results using a single…